US 11,987,610 B2
T-cell modulatory multimeric polypeptides and methods of use thereof
Ronald D. Seidel, III, Boston, MA (US); and Rodolfo J. Chaparro, Cambridge, MA (US)
Assigned to Cue Biopharma, Inc., Boston, MA (US)
Filed by Cue Biopharma, Inc., Boston, MA (US)
Filed on Nov. 10, 2023, as Appl. No. 18/388,792.
Application 18/388,792 is a continuation of application No. 18/202,596, filed on May 26, 2023, granted, now 11,905,320.
Application 18/202,596 is a continuation of application No. 17/845,583, filed on Jun. 21, 2022, granted, now 11,708,400, issued on Jul. 25, 2023.
Application 17/845,583 is a continuation of application No. 17/578,094, filed on Jan. 18, 2022, granted, now 11,377,478, issued on Jul. 5, 2022.
Application 17/578,094 is a continuation of application No. 17/507,113, filed on Oct. 21, 2021, granted, now 11,370,821, issued on Jun. 28, 2022.
Application 17/507,113 is a continuation of application No. 17/386,109, filed on Jul. 27, 2021, abandoned.
Application 17/386,109 is a continuation of application No. 17/176,777, filed on Feb. 16, 2021, granted, now 11,117,945, issued on Sep. 14, 2021.
Application 17/176,777 is a continuation of application No. 16/812,926, filed on Mar. 9, 2020, granted, now 10,927,158, issued on Feb. 23, 2021.
Application 16/812,926 is a continuation of application No. 16/741,202, filed on Jan. 13, 2020, abandoned.
Application 16/741,202 is a continuation of application No. 16/462,443, abandoned, previously published as PCT/US2017/067663, filed on Dec. 20, 2017.
Claims priority of provisional application 62/582,132, filed on Nov. 6, 2017.
Claims priority of provisional application 62/555,435, filed on Sep. 7, 2017.
Claims priority of provisional application 62/470,774, filed on Mar. 13, 2017.
Claims priority of provisional application 62/438,272, filed on Dec. 22, 2016.
Prior Publication US 2024/0083964 A1, Mar. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/55 (2006.01); A61K 9/00 (2006.01); A61K 35/17 (2015.01); C07K 14/005 (2006.01); C07K 14/47 (2006.01); C07K 14/74 (2006.01); G01N 33/50 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 14/55 (2013.01) [A61K 9/0019 (2013.01); A61K 35/17 (2013.01); C07K 14/005 (2013.01); C07K 14/4748 (2013.01); C07K 14/70539 (2013.01); G01N 33/5008 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2319/30 (2013.01)] 15 Claims
 
1. A fusion polypeptide comprising:
a) a plurality of variant IL-2 polypeptides, wherein the plurality consists of a first variant IL-2 polypeptide and a second variant IL-2 polypeptide, wherein the first and second variant IL-2 polypeptides have the amino acid sequence set forth in SEQ ID NO:84, and wherein the first and second variant IL-2 polypeptides are joined by a linker; and
b) a heterologous fusion partner, wherein the heterologous fusion partner does not comprise a major histocompatibility complex (MHC) polypeptide, and wherein the heterologous fusion partner is an antibody Fc region having at least 98% sequence identity to the amino acid sequence set forth in SEQ ID NO:57, wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST, and
wherein the fusion polypeptide comprises from 500 to 600 amino acids.